Document:

Revett Minerals Inc.: Exhibit 10.4 - Filed by newsfilecorp.com

EXHIBIT 10.4

REVETT MINERALS INC.
AMENDED AND RESTATED EQUITY
INCENTIVE PLAN

SECTION 1
PURPOSE

	1.1 	
      The purpose of this Equity Incentive Plan is to provide a
      means whereby Revett Minerals Inc., a Canadian corporation (the
      “Corporation”), may attract able persons to remain in or to enter the
      employ of the Corporation or a Subsidiary of the Corporation and to
      provide a means whereby those employees, officers, directors and other
      individuals or entities upon whom the responsibilities of the successful
      administration, management, planning, and/or organization of the
      Corporation may rest, and whose present and potential contributions to the
      welfare of the Corporation or a Subsidiary of the Corporation are of
      importance, can acquire and maintain stock ownership, thereby
      strengthening their concern for the long-term welfare of the Corporation.
      A further purpose of the Plan is to provide such employees and individuals
      or entities with additional incentive and reward opportunities designed to
      enhance the profitable growth of the Corporation over the long term.
      Accordingly, the Plan provides for the grant of Incentive Stock Options,
      options which do not constitute Incentive Stock Options, Stock
      Appreciation Rights or any combination of the foregoing and for the
      issuance of Common Shares in satisfaction of amounts owing for
      services.

SECTION 2
DEFINITIONS

	2.1 	
      The following definitions shall be applicable during the
      term of the Plan unless specifically modified by any paragraph:

	 	 	 
		(a) 	
      “Affiliated Entity” has the meaning ascribed
      thereto by Multilateral Instrument 52-110, as the same may be amended from
      time to time.

	 	 	 
		(b) 	
      “Associate” has the meaning ascribed thereto in
      the Securities Act (Ontario), as the same may be amended from time
      to time.

	 	 	 
		(c) 	
      “Award” means, individually or collectively, any
      Option granted pursuant to the Plan.

	 	 	 
		(d) 	
      “Board” means the board of directors of the
      Corporation.

	 	 	 
		(e) 	
      “CBCA” means the Canada Business Corporations
      Act.

	 	 	 
		(f) 	
      “Code” means the Internal Revenue Code of 1986, as
      amended. Reference in the Plan to any Section of the Code shall be deemed
      to include any amendments or successor provisions to such Section and any
      regulations under such Section.

	 	(g) 	
      “Committee” means a committee of the Board which
      is given authority by the Board to recommend Awards or Options under the
      Plan.

	 	 	 	 
	 	(h) 	
      “Common Shares” means the common shares of the
      Corporation.

	 	 	 	 
	 	(i) 	
      “Corporate Change” means one of the following
      events:

	 	 	 	 
	 		(i) 	
      the merger, arrangement, amalgamation, reorganization or
      other similar transaction involving the Corporation in which the
      outstanding Common Shares are converted into or exchanged for a different
      class of securities of the Corporation, a class of securities of any other
      issuer (except a Subsidiary of the Corporation), cash or other property
      other than (A) a merger, arrangement, amalgamation, reorganization or
      other similar transaction involving the Corporation which would result in
      the voting shares of the Corporation outstanding immediately prior thereto
      continuing to represent (either by remaining outstanding or by being
      converted into voting securities of the surviving entity) at least sixty
      percent (60%) of the combined voting power of the voting shares of the
      Corporation or such surviving entity outstanding immediately after such
      merger, arrangement, amalgamation, reorganization or other similar
      transaction involving the Corporation, or (B) merger, arrangement,
      amalgamation, reorganization or other similar transaction involving the
      Corporation effected to implement a recapitalization of the Corporation
      (or similar transaction) in which no person acquires more than forty-nine
      percent (49%) of the combined voting power of the Corporation’s then
      outstanding shares;

	 	 	 	 
	 		(ii) 	
      the sale, lease or exchange of all or substantially all
      of the assets of the Corporation to any other corporation or entity
      (except a Subsidiary of the Corporation);

	 	 	 	 
	 		(iii) 	
      the adoption by the shareholders of the Corporation of a
      resolution to liquidate or dissolve the Corporation;

	 	 	 	 
	 		(iv) 	
      the acquisition (other than acquisition pursuant to any
      other clause of this definition) by any person or group of persons, of
      beneficial ownership of more than twenty-five percent (25%) (based on
      voting power) of the Corporation’s outstanding Common Shares or
      acquisition by a person or group of persons who currently has beneficial
      ownership which increases such person’s or group’s beneficial ownership to
      fifty percent (50%) or more (based on voting power) of the Corporation’s
      outstanding Common Shares; or

	 	 	 	 
	 		(v) 	
      as a result of or in connection with a contested election
      of directors, the persons who were directors of the Corporation before
      such election shall cease to constitute a majority of the Board.

	 	 	 	 
	 	(j) 	
      “Corporation” means Revett Minerals
  Inc.

- 2 -

	 	(k) 	
      “Current Market Price” means, as of any specified
      date, the price per share equal to the weighted average price at which the
      Common Shares have traded on the Toronto Stock Exchange (or, if the Common
      Shares are not then listed on such exchange, such other stock exchange or
      over the counter market on which the Common Shares are then listed or
      quoted) during the period of any twenty consecutive trading days ending
      not more than five (5) trading days before such date; provided that the
      weighted average price shall be determined by dividing the aggregate sale
      price of all Common Shares sold on the said exchange or market, as the
      case may be, during the said twenty consecutive trading days by the total
      number of Common Shares so sold. If the Common Shares are not then listed
      or quoted on any stock exchange or over the counter market, at the time
      determination of its Current Market Price is required to be made
      hereunder, the determination of its Current Market Price shall be made by
      the Board in such manner as it deems appropriate.

	 	 	 
	 	(l) 	
      “Eligible Recipient” means: (i) any employee,
      officer, director or consultant (as defined in National Instrument 45-106,
      as the same may be amended from time to time) of the Corporation or an
      Affiliated Entity of the Corporation; or (ii) a permitted assign (as
      defined in National Instrument 45-106, as the same may be amended from
      time to time) of a person or company referred to in paragraph
  (i).

	 	 	 
	 	(m) 	
      “Exchange Act” means the Securities Exchange Act
      of 1934, as amended.

	 	 	 
	 	(n) 	
      “Fair Market Value” means, as of any specified
      date, the closing price of the Common Shares on the Toronto Stock Exchange
      (or, if the Common Shares are not listed on such exchange, such other
      stock exchange on which the Common Shares are then listed) on the trading
      day immediately preceding that date, or if no prices are reported on that
      date, on the last preceding date on which such prices of the Common Shares
      are so reported. If the Common Shares are not then listed on any stock
      exchange but is traded over the counter at the time determination of its
      Fair Market Value is required to be made hereunder, its Fair Market Value
      shall be deemed to be equal to the average between the reported high and
      low sales prices of Common Shares on the most recent date on which Common
      Shares were publicly traded. If the Common Shares are not publicly traded
      at the time a determination of its value is required to be made hereunder,
      the determination of its Fair Market Value shall be made by the Board in
      such manner as it deems appropriate (such determination will be made in
      good-faith as required by Section 422(c)(1) of the Code and may be based
      on the advice of an independent investment banker or appraiser recognized
      to be expert in making such valuations).

	 	 	 
	 	(o) 	
      “Grant” means individually or collectively, any
      Stock Appreciation Right granted pursuant to the Plan or any issuance of
      Common Shares pursuant to the Plan in satisfaction of amounts owing for
      services.

- 3 -

	 	(p) 	
      “Grantee” means an Eligible Recipient who has been
      granted Stock Appreciation Rights pursuant to the Plan or who has been
      issued Common Shares pursuant to the Plan in satisfaction of amounts owing
      for services.

	 	 	 
	 	(q) 	
      “Incentive Stock Option” means an Option within
      the meaning of Section 422 of the Code.

	 	 	 
	 	(r) 	
      “Insider” means an insider of the Corporation
      within the meaning of the rules, regulations and policies of the Toronto
      Stock Exchange from time to time for purposes of securities based
      compensation arrangements.

	 	 	 
	 	(s) 	
      “Option” means an Award granted under Section 7 of
      the Plan and includes both Incentive Stock Options to purchase Common
      Shares and Options which do not constitute Incentive Stock Options to
      purchase Common Shares.

	 	 	 
	 	(t) 	
      “Option Agreement” means a written agreement
      between the Corporation and an Optionee with respect to an
  Option.

	 	 	 
	 	(u) 	
      “Optionee” means an Eligible Recipient who has
      been granted an Option.

	 	 	 
	 	(v) 	
      “Plan” means this amended and restated Equity
      Incentive Plan.

	 	 	 
	 	(w) 	
      “Rule 16b-3” means Rule 16b-3 of the General Rules
      and Regulations of the Securities and Exchange Commission under the
      Exchange Act, as such rule is currently in effect or as hereafter modified
      or amended.

	 	 	 
	 	(x) 	
      “Share Compensation Arrangement” means a stock
      option, stock option plan, employee stock purchase plan or any other
      compensation or incentive mechanism of the Corporation involving the
      issuance or potential issuance of shares of the Corporation to one or more
      Eligible Recipients, including a share purchase from the treasury of the
      Corporation which is financially assisted by the Corporation by way of a
      loan, guarantee or otherwise.

	 	 	 
	 	(y) 	
      “Stock Appreciation Rights” means the right to
      receive the increase in the value of Common Shares subject to an Option in
      lieu of purchasing such Common Shares.

	 	 	 
	 	(z) 	
      “Subsidiary” has the meaning ascribed thereto by
      the Securities Act (Ontario), except that solely with respect to
      the issuance of Incentive Stock Options, the term “Subsidiary” shall have
      the same meaning as the term “subsidiary corporation” as defined in
      Section 424(f) of the Code.

SECTION 3
EFFECTIVE DATE

	3.1 	
      The Plan shall be effective on January 26,
  2005.

- 4 -

SECTION 4
ADMINISTRATION

	4.1 	
      Administration of Plan by Board. The Plan shall be
      administered by the Board or by a committee (“Committee”) of the
      Board established by the Board for that purpose. Members of the Board
      shall abstain from participating in and deciding matters which directly
      affect their individual ownership interests under the Plan.

	 	 	 
	4.2 	
      Powers. Subject to the terms of the Plan, the
      Board or Committee shall have the power, where consistent with the general
      purpose and intent of the Plan and subject to the specific provisions of
      the Plan:

	 	 	 
		(a) 	
      to determine those Eligible Recipients that should be
      given an Award or Grant;

	 	 	 
		(b) 	
      to determine when such Award or Grant should be
    made;

	 	 	 
		(c) 	
      to determine the type of Award or Grant (Stock
      Appreciation Rights, Incentive Stock Option, non-qualified Option or
      Common Share issuance); and

	 	 	 
		(d) 	
      to determine the number of Common Shares that should be
      awarded or granted.

	 	 	 
		
      In making such determinations, the Board may take into
      account the nature of the services rendered by these individuals, their
      present and potential contribution to the success of the Corporation or a
      Subsidiary of the Corporation, and such other factors as the Board in its
      discretion shall deem relevant.

	 	 	 
	4.3 	
      Additional Powers. The Board shall have such
      additional powers as are delegated to it by the other provisions of the
      Plan. Subject to the express provisions of the Plan, the Board is
      authorized in its sole discretion, to construe and interpret the Plan and
      the respective agreements executed thereunder, to prescribe such rules and
      regulations relating to the Plan as it may deem advisable to carry out the
      Plan, and to determine the terms, restrictions and provisions of each
      Award or Grant, including such terms, restrictions and provisions as shall
      be requisite in the judgment of the Board to cause designated Options to
      qualify as Incentive Stock Options, and to make all other determinations
      necessary or advisable for administering the Plan. The Board may correct
      any defect or supply any omission or reconcile any inconsistency in any
      agreement relating to an Award or Grant in the manner and to the extent it
      shall deem expedient to carry it into effect. The determination of the
      Board on the matters referred to in this Section 4 shall be
    conclusive.

	 	 	 
	4.4 	
      Compliance with Law. Any Award or Grant granted
      under the Plan shall be subject to the requirement that, if at any time
      counsel to the Corporation shall determine that the listing, registration
      or qualification of the Common Shares subject to such Award or Grant upon
      any stock exchange or under any law or regulation of any jurisdiction, or
      the consent or approval of any stock exchange or any governmental or
      regulatory body, is necessary as a condition of, or in connection with,
      the grant or exercise of such Award or Grant or the issuance or purchase
      of Common Shares thereunder, such Award or Grant may not be accepted or
      exercised in whole or in part unless such listing,
  registration, qualification, consent or approval shall have been
      effected or obtained on conditions acceptable to the Board or the
      Committee. Nothing herein shall be deemed to require the Corporation to
      apply for or to obtain such listing, registration, qualification, consent
  or approval.

- 5 -

		
      Without limiting the generality of the foregoing, unless
      a registration statement relating to the Common Shares covered by an Award
      or Grant issued in favour of an Optionee or Grantee resident in the United
      States of America has been filed with the United States Securities and
      Exchange Commission and is effective on the date of exercise, the exercise
      of the Award or Grant by such Optionee or Grantee will be contingent upon
      receipt from the Optionee or Grantee of a representation in writing
      satisfactory to the Corporation that at the time of such exercise it is
      the Optionee's or Grantee’s then intention to acquire the Common Shares
      being purchased for investment and not for resale or other distribution
      thereof to the public in the United States of America.

	 	 
		
      The Corporation may in its discretion inscribe a legend
      on any share certificates issued pursuant to the exercise of an Award or
      Grant. The issuance of Common Shares upon the exercise of the Award or
      Grant shall be subject to all applicable laws, rules and regulations and
      Common Shares shall not be issued except upon the approval of proper
      government agencies or stock exchanges as may be required. Provided,
      however, the Award or Grant shall not be exercisable if at any date of
      exercise, it is the opinion of counsel for the Corporation that
      registration of the said Common Shares under the Securities Act of 1933 or
      other applicable statute or regulation is required and the Award or Grant
      shall again become exercisable only if the Corporation elects to and
      thereafter effects a registration of the Common Shares subject to the
      Award or Grant under the Securities Act of 1933 or other applicable
      statute or regulation within the relevant period. If the Award or Grant
      may not be exercised, the Corporation shall return to the Optionee or
      Grantee, without interest or deduction, any funds received by it in
      connection with the proposed exercise of the Award or Grant.

	 	 
	4.5 	
      Compliance With Code §162(m). In the event the
      Corporation or a Subsidiary of the Corporation becomes a “publicly-held
      corporation” as defined in Section 162(m)(2) of the Code, the Corporation
      may establish a committee of outside directors meeting the requirements of
      Code § 162(m) to (i) approve the grant of Options which might reasonably
      be anticipated to result in the payment of employee remuneration that
      would otherwise exceed the limit on employee remuneration deductible for
      income tax purposes by the Corporation pursuant to Code §162(m) and (ii)
      administer the Plan. In such event, the powers reserved to the Board in
      the Plan shall be exercised by such committee. In addition, Options under
      the Plan shall be granted upon satisfaction of the conditions to such
      grants provided pursuant to Code §162(m) and any Treasury Regulations
      promulgated thereunder.

SECTION 5
SHARES SUBJECT TO THE PLAN

	5.1 	
      Award Limits. The total number of shares issued
      under this Plan, together with the total number of shares issued under any
      other Share Compensation Arrangement, shall not
exceed 6,500,000 Common Shares or such greater number of Common
      Shares as may be determined by the Board and approved by any relevant
      stock exchange or other regulatory authority and, if required, by the
      shareholders of the Corporation. No Options shall be granted to any one
      Optionee if the total number of Common Shares reserved for issuance to
      such Optionee under this Plan, together with any Common Shares reserved
      for issuance to such Optionee under any other stock option arrangement,
      would exceed 5% of the issued and outstanding Common Shares at the time of
      such grant. The Corporation shall at all times reserve a sufficient number
      of shares to meet the requirements of the Plan. Shares shall be deemed to
      have been issued under the Plan only to the extent actually issued and
      delivered pursuant to an Award or Grant. To the extent that an Award or
      Grant expires unexercised, any Common Shares subject to such Award or
      Grant shall again be available for the grant of an Award or making of a
      Grant. The aggregate number of shares which may be issued under the Plan
      shall be subject to adjustment in the same manner as provided in Section 8
      of the Plan with respect to Common Shares subject to Options then
  outstanding.

- 6 -

	5.2 	
      Stock Appreciation Rights. A Stock Appreciation
      Right may, in the case of a non- qualified Option, be granted at the time
      the Option is granted or at any time thereafter during the term of the
      Option. Stock Appreciation Rights may only be granted, in connection with
      Incentive Stock Options, at the time the Options are granted. Upon
      exercising a Stock Appreciation Right the holder of the related Option
      shall, upon surrender of such Option or any portion thereof to the extent
      unexercised, receive payment of an amount determined by multiplying (i)
      the excess of Current Market Price for the Common Shares on the date of
      exercise of such Stock Appreciation Right over the Option Price under the
      related Option, by (ii) the number of shares as to which such Stock
      Appreciation Right has been exercised. Notwithstanding the foregoing, the
      agreement evidencing the Stock Appreciation Right may limit in any manner
      the amount payable with respect to any Stock Appreciation Right.

	 	 
		
      A Stock Appreciation Right shall be exercisable at such
      time or times and only to the extent that a related Option is exercisable,
      and shall not be transferable. A Stock Appreciation Right granted in
      connection with an Incentive Stock Option shall be exercisable only if the
      Current Market Price of the Common Shares on the date of exercise is
      greater than the Option Price of the related Option. Upon the exercise of
      a Stock Appreciation Right, the related Option shall be cancelled to the
      extent of the number of Common Shares as to which the Stock Appreciation
      Right is exercised, and upon the exercise of an Option granted in
      connection with a Stock Appreciation Right, the Stock Appreciation Right
      shall be cancelled to the extent of the number Common Shares as to which
      the Option is exercised or surrendered. The Grantee shall exercise a Stock
      Appreciation Right by delivering a written notice of exercise to the
      Secretary of the Corporation and providing the Secretary with the
      agreements evidencing the Stock Appreciation Right and any related
      Option.

	 	 
		
      Payment of the appreciated value of the Common Shares may
      be made by the Corporation at the discretion of the Board, solely in cash,
      Common Shares, or a combination of cash and Common Shares. Subject to the
      terms of the Plan, the Board may modify outstanding grants of Stock
      Appreciation Rights or accept the surrender of outstanding grants of Stock
Appreciation Right (to the extent not exercised) and make new grants in
substitution thereof. Notwithstanding the foregoing no modification to the grant
of a Stock Appreciation Right shall adversely alter or impair any rights or
obligations under the agreement granting such Stock Appreciation Right without
the Grantee’s consent.

- 7 -

SECTION 6
STOCK OPTION ELIGIBILITY

	6.1 	
      An Incentive Stock Option Award made pursuant to the Plan
      may be granted only to an individual who, at the time of grant, is an
      employee of the Corporation or a Subsidiary of the Corporation. An Award
      of an Option which is not an Incentive Stock Option may be made to an
      individual who, at the time of Award, is an employee of the Corporation or
      a Subsidiary of the Corporation, or to an individual who has been
      identified by the Board or Committee to receive an Award due to their
      contribution or service to the Corporation, including members of the Board
      or the board of directors of a Subsidiary of the Corporation. An Award
      made pursuant to the Plan may be made on more than one occasion to the
      same person, and such Award may include a grant of an Incentive Stock
      Option, an Option which is not an Incentive Stock Option, or any
      combination thereof. Each Award shall be evidenced by a written instrument
      duly executed by or on behalf of the Corporation.

SECTION 7
STOCK OPTIONS/GRANTS

	7.1 	
      Stock Option Agreement. Each Option shall be
      evidenced by an Option Agreement between the Corporation and the Optionee
      which shall contain such terms and conditions as may be approved by the
      Board. The terms and conditions of the respective Option Agreements need
      not be identical.

	 	 
	7.2 	
      Option Period. The term of each Option shall be
      the lesser of 10 years and the term as specified by the Board at the date
      of grant and stated in the Option Agreement.

	 	 
	7.3 	
      Limitations on Exercise of Option. Any Option
      granted hereunder shall be exercisable at such times and under such
      conditions as determined by the Board and as shall be permissible under
      the terms of the Plan, which shall be specified in the Option Agreement
      evidencing the Option. The Board or Committee may, in their discretion,
      subsequent to the time of granting Options hereunder, permit an Optionee
      to exercise any or all of the unvested Options then outstanding, in which
      event such unvested Options shall be deemed to be exercisable during such
      period of time as may be specified by the Board or Committee. An Option
      may not be exercised for fractional shares.

	 	 
	7.4 	
      Special Limitations on Incentive Stock Options. To
      the extent that the aggregate Fair Market Value (determined at the time
      the respective Incentive Stock Option is granted) of Common Shares with
      respect to which Incentive Stock Options are exercisable for the first
      time by an individual during any calendar year under all incentive stock
      option plans of the Corporation (and any Subsidiary of the Corporation)
      exceeds One Hundred Thousand U.S. Dollars (U.S.$100,000) (within the meaning
      of Section 422 of the Code), such excess Incentive Stock Options shall be
      treated as Options which do not constitute Incentive Stock Options. The
      Board shall determine, in accordance with applicable provisions of the
      Code, Treasury Regulations and other administrative pronouncements, which
      of an Optionee’s Incentive Stock Options will not constitute Incentive
      Stock Options because of such limitation and shall notify the Optionee of
      such determination as soon as practicable after such determination. No
      Incentive Stock Option shall be granted to an individual if, at the time
      the Option is granted, such individual owns shares to which are attached
      more than ten percent (10%) of the total combined voting power of all
      classes of shares of the Corporation or of a Subsidiary of the
      Corporation, within the meaning of Section 422(b)(6) of the Code, unless
      (i) at the time such Option is granted the Option price is at least one
      hundred ten percent (110%) of the Fair Market Value of the Common Shares
      subject to the Option and (ii) such Option by its terms is not exercisable
after the expiration of five years from the date of grant.

- 8 -

	7.5 	
      Option Price. The purchase price of Common Shares
      issued under each Option shall be determined by the Board and shall be
      stated in the Option Agreement, but such purchase price shall, in the case
      of Incentive Stock Options, not be less than the Fair Market Value of
      Common Shares subject to the Option on the date the Option is granted,
      except that the price shall be one hundred ten percent (110%) of the fair
      value in the case of any person or entity who owns shares to which are
      attached more than ten percent (10%) of the total combined voting power of
      all classes of shares of the Corporation or of a Subsidiary of the
      Corporation.

	 	 
	7.6 	
      Options and Rights in Substitution for Stock Options
      Made by Other Corporations.

	 	 
		
      Options may be granted under the Plan from time to time
      in substitution for stock options held by employees of corporations who
      become, or who became prior to the effective date of the Plan, employees
      of the Corporation or of any Subsidiary of the Corporation as a result of
      a merger or consolidation of the employing corporation with the
      Corporation or such Subsidiary of the Corporation, or the acquisition by
      the Corporation or a Subsidiary of the Corporation of all or a portion of
      the assets of the employing corporation, or the acquisition by the
      Corporation or a Subsidiary of the Corporation of shares of the employing
      corporation with the result that such employing corporation becomes a
      Subsidiary of the Corporation.

	 	 
	7.7 	
      Subscription Agreement for Share Issuance. Each
      issuance of Common Shares in satisfaction of amounts owing for services
      shall be evidenced by a Subscription Agreement which shall contain such
      restrictions, terms and conditions as the Board may determine in its
      discretion. Such restrictions, terms and conditions may, without
      limitation, include a restriction on the number of such Common Shares that
      may be sold at any given time.

- 9 -

SECTION 8
ADJUSTMENTS IN THE EVENT OF CERTAIN
CHANGES
IN CAPITAL STRUCTURE

	8.1 	
      Except as hereinafter otherwise provided, Awards or
      Grants shall be subject to adjustment by the Board at its discretion as to
      the number and price of Common Shares in the event of changes in the
      outstanding Common Shares by reason of stock splits, reverse stock splits,
      reclassifications, recapitalizations, reorganizations, mergers,
      consolidations, combinations, exchanges or other relevant changes in
      capitalization occurring after the date of the grant of any such Awards or
      Options.

	 	 
		
      In the event of a Corporate Change, the Board shall
      either at the time Awards or Options are awarded or granted, or if so
      provided in the applicable Option Agreement, at any time thereafter, have
      the authority to take such actions as it deems advisable, including,
      without limitation (a) the right to accelerate in whole or in part the
      exercisability of Options, (b) to require the mandatory surrender of
      outstanding Options in exchange for cash for the bargain element the
      Optionee would have realized upon the occurrence of the Corporate Change,
      if any, (c) provide that upon exercise of the Option, the Optionee will be
      entitled to purchase other securities or property, or (d) cancel the
      Options if the Fair Market Value of the Common Shares which underlies the
      Options is below the Option exercise price. The Option Agreement may
      contain provisions which, in the event of a Corporate Change,
      automatically or at the discretion of the Board accelerate the
      exercisability of Options. Nothing herein shall obligate the Board to take
      any action upon a Corporate Change.

	 	 
	8.2 	
      The existence of the Plan and the Awards and/or Grants
      made hereunder shall not affect in any way the right or power of the Board
      or the shareholders of the Corporation to make or authorize any
      adjustment, recapitalization, reorganization or other change in the
      capital structure of the Corporation or a Subsidiary of the Corporation or
      their business, any merger or consolidation of the Corporation or a
      Subsidiary of the Corporation, any issue of debt or equity securities
      having any priority or preference with respect to or affecting Common
      Shares or the rights thereof, the dissolution or liquidation of the
      Corporation or a Subsidiary of the Corporation, or any sale, lease,
      exchange or other disposition of all or any part of their assets or
      business or any other corporate act or proceeding.

	 	 
	8.3 	
      The shares with respect to which Options may be granted
      are Common Shares as presently constituted but if and whenever, prior to
      the expiration of an Option theretofore granted, the Corporation shall
      effect a subdivision or consolidation of Common Shares or the payment of a
      stock dividend on Common Shares without receipt of consideration by the
      Corporation, the number of Common Shares with respect to which such Option
      may thereafter be exercised (i) in the event of an increase in the number
      of outstanding shares shall be proportionately increased, and the purchase
      price per share shall be proportionately reduced, and (ii) in the event of
      a reduction in the number of outstanding shares shall be proportionately
      reduced, and the purchase price per share shall be proportionately
      increased.

- 10 -

	8.4 	
      If the Corporation recapitalizes or otherwise changes its
      capital structure, thereafter upon any exercise of an Option theretofore
      granted, the Optionee shall be entitled to purchase under such Option, in
      lieu of the number of Common Shares as to which such Option shall then be
      exercisable, the number and class of shares and securities, and the cash
      and other property to which the Optionee would have been entitled pursuant
      to the terms of the recapitalization if, immediately prior to such
      recapitalization, the Optionee had been the holder of record of the number
      of shares then covered by such Option.

SECTION 9
AMENDMENT OR TERMINATION OF THE
PLAN

	9.1 	
      The Board may at any time, subject to the provisions of
      Section 9.2 below, amend, suspend or terminate this Plan, or any portion
      thereof, provided that no change in any Award or Grant previously made may
      be made which would impair the rights of the Optionee or Grantee
      thereunder without the consent of the affected Optionee or Grantee.
      Without limiting the generality of the foregoing, the Board may make the
      following types of amendments to the Plan without shareholder
    approval:

	 	 	 
		(a) 	
      amendments of a ministerial nature including, without
      limiting the generality of the foregoing, any amendment for the purpose of
      curing any ambiguity, error or omission in the Plan or to correct or
      supplement any provision of the Plan that is inconsistent with any other
      provision of the Plan;

	 	 	 
		(b) 	
      amendments necessary to comply with the provisions of
      applicable law (including, without limitation, the rules, regulations and
      policies of the Toronto Stock Exchange);

	 	 	 
		(c) 	
      amendments respecting administration of the
  Plan;

	 	 	 
		(d) 	
      any amendment to the vesting provisions of the Plan or
      any Option;

	 	 	 
		(e) 	
      any amendment to the early termination provisions of the
      Plan or any Option, whether or not such Option is held by an Insider,
      provided such amendment does not entail an extension beyond the original
      expiry date;

	 	 	 
		(f) 	
      any amendment to the termination provisions of the Plan
      or any Option, other than an amendment extending the term of an Option,
      provided any such amendment does not entail an extension of the expiry
      date of such Option beyond its original expiry date;

	 	 	 
		(g) 	
      the addition or modification of any form of financial
      assistance by the Corporation;

	 	 	 
		(h) 	
      the addition or modification of a cashless exercise
      feature, payable in cash or Common Shares, whether or not there is a full
      deduction of the number of Common Shares from the Plan reserve;
  and

- 11 -

		(i) 	
      any other amendments, whether fundamental or otherwise,
      not requiring shareholder approval under applicable law (including without
      limitation, the rules, regulations and policies of the Toronto Stock
      Exchange).

	 	 	 
	9.2 	
      Shareholder approval will be required for the following
      types of amendments to the Plan:

	 	 	 
		(a) 	
      amendments to the number of Common Shares issuable under
      the Plan, including an increase to a fixed maximum number of Common Shares
      or a change from a fixed maximum number of Common Shares to a fixed
      maximum percentage;

	 	 	 
		(b) 	
      any amendment which reduces the exercise price of an
      Option or a cancellation and re-grant at a lower price less than three
      months after the related cancellation;

	 	 	 
		(c) 	
      any amendment extending the term of an Option beyond its
      original expiry date;

	 	 	 
		(d) 	
      any amendment broadening any limits imposed on
      non-employee director participation under the Plan;

	 	 	 
		(e) 	
      any amendment respecting transferability or assignability
      of Awards or Options under the Plan, other than for normal estate
      settlement purposes; and

	 	 	 
		(f) 	
      amendments required to be approved by shareholders under
      applicable law (including, without limitation, the rules, regulations and
      polices of the Toronto Stock Exchange).

	 	 	 
	9.3 	
      In the event of any conflict between the provisions of
      Section 9.1 and Section 9.2, the provisions of Section 9.2 shall prevail
      to the extent of the conflict.

SECTION 10
OTHER

	10.1 	
      No Right to an Award or Grant. Neither the
      adoption of the Plan nor any action of the Board or Committee shall be
      deemed to give an employee any right to be granted an Option to purchase
      Common Shares, to receive a Grant or to any other rights hereunder except
      as may be evidenced by an Option Agreement duly executed on behalf of the
      Corporation, and then only to the extent of and on the terms and
      conditions expressly set forth therein. The Plan shall be unfunded. The
      Corporation shall not be required to establish any special or separate
      fund or to make any other segregation of funds or assets to assure the
      payment of any Award or Grant.

	 	 
	10.2 	
      No Employment Rights Conferred. Nothing contained
      in the Plan or in any Award or Grant made hereunder shall (i) confer upon
      any employee any right with respect to continuation of employment with the
      Corporation or Subsidiary of the Corporation, or
(ii) interfere in any way with the right of the Corporation or
      Subsidiary of the Corporation to terminate his or her employment at any
  time.

- 12 -

	10.3 	
      Other Laws; Withholding. The Corporation shall not
      be obligated to issue any Common Shares pursuant to any Award or Grant
      made under the Plan at any time if, in the opinion of legal counsel for
      the Corporation, there is no exemption from the prospectus or registration
      requirements of applicable laws, rules or regulations available for the
      issuance and sale of such shares. No fractional Common Shares shall be
      delivered, nor shall any cash in lieu of fractional shares be paid. The
      Corporation shall have the right to deduct in connection with all Awards
      or Grants any taxes required by law to be withheld and to require any
      payments necessary to enable it to satisfy its withholding obligations.
      The Board may permit the holder of an Award or Grant to elect to
      surrender, or authorize the Corporation to withhold Common Shares (valued
      at their Fair Market Value on the date of surrender or withholding of such
      shares) in satisfaction of the Corporation’s withholding obligation,
      subject to such restrictions as the Board deems necessary to satisfy the
      requirements of Rule 16b 3.

	 	 
	10.4 	
      No Restriction of Corporate Action. Nothing
      contained in the Plan shall be construed to prevent the Corporation or
      Subsidiary of the Corporation from taking any corporate action which is
      deemed by the Corporation or Subsidiary of the Corporation to be
      appropriate or in its best interest, whether or not such action would have
      an adverse effect on the Plan or any Award or Grant made under the Plan.
      No employee, beneficiary or other person shall have any claim against the
      Corporation or Subsidiary of the Corporation as a result of such
      action.

	 	 
	10.5 	
      Restrictions on Transfer. An Award shall not be
      transferable otherwise than by will or the laws of descent and
      distribution and shall be exercisable during the lifetime of the Optionee
      only by such Optionee or the Optionee’s guardian or legal
      representative.

	 	 
	10.6 	
      Effect of Death, Disability or Termination of
      Employment. Each Option Agreement shall specify the effect of
      termination of employment (whether by resignation, termination for “cause”
      or otherwise), total and permanent disability, retirement or death on the
      exercisability of the Option. A determination by the Corporation that an
      Optionee was discharged for “cause” shall be binding on the Optionee for
      the purposes of the Plan. For the purposes of the Plan, the date of
      termination of employment shall be deemed to be the date notice of
      termination is actually given, without regard to any notice period
      applicable under contract or at law.

	 	 
		
      All outstanding Incentive Stock Options will
      automatically be converted to a non- qualified stock option if the
      Optionee does not exercise the Incentive Stock Option (i) within three (3)
      months of the date of termination caused by reasons other than death or
      disability; or (ii) within twelve (12) months of the date of termination
      caused by death and disability.

	 	 
	10.7 	
      Rule 16b 3. It is intended that the Plan and any
      grant of an Award made to a person subject to Section 16 of the Exchange
      Act meet all of the requirements of Rule 16b-3. If any provisions of the
      Plan or any such Award would disqualify the Plan or such
  Award hereunder, or would otherwise not comply with Rule 16b 3,
      such provision or Award shall be construed or deemed amended to conform to
  Rule 16b 3.

- 13 -

	10.8 	
      Governing Law. The Plan shall by construed in
      accordance with the laws of the Province of Ontario and the laws of Canada
      applicable therein.

	 	 	 
	10.9 	
      Limits on Insiders. The Awards or Grants to
      Insiders shall be subject to the following two limitations:

	 	 	 
		(a) 	
      the number of Common Shares issuable to Insiders, at any
      time, under all Share Compensation Arrangements, may not exceed 10% of the
      Corporation’s issued and outstanding Common Shares; and

	 	 	 
		(b) 	
      the number of Common Shares issued to Insiders, within
      any one year period, under all Share Compensation Arrangements, may not
      exceed 10% of the Corporation’s issued and outstanding Common
    Shares.

- 14 -

     ADOPTED BY THE BOARD OF DIRECTORS
OF REVETT MINERALS INC. AS OF JANUARY 26, 2005 AND AMENDED AND RESTATED BY THE
BOARD OF DIRECTORS OF REVETT MINERALS INC. AS OF MARCH 23, 2007 AND AS OF MAY
13, 2009.

     APPROVED BY THE SHAREHOLDERS OF
REVETT MINERALS INC. AS OF JANUARY 26, 2005, WITH AMENDMENTS APPROVED BY THE
SHAREHOLDERS OF REVETT MINERALS INC. AS OF JUNE 19, 2007, JUNE 16, 2009 AND JUNE
21, 2011.

- 15 -Exhibit 10.1 Agency Agreement

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Exhibit 10.1

Agency Agreement

This agreement ("Agreement") is entered into on this 10th day of March, 2012 (“the Effective Date”), between Fuel Doctor Holdings, Inc., located at 23961 Craftsman Road, #L, Calabasas, California 91302 (the “Company”),  IMPEX HOLDING CO LTD located at, Piyaplace Building 6th floor, Tower B, Room 6C 29/1 Soi Langsuan, Ploenchit Road, Lumpini Patumwan, Bangkok, 10330, Thailand (the “Agent”).  

Whereas, the Company engages in manufacturing, marketing and distribution of a fuel saving component, which reduces the utilization of fuel known as “Fuel Doctor FD-47 and FD-65” (the “Product(s)”); 

Whereas, the Agent is in the business of distribution and marketing of such product and represents to the Company that it has the experience, knowledge, know-how, marketing connections and ability to market and distribute the Products to potential clients in Italy, France, Spain, Greece and Poland (the “Territory”); and 

Whereas, the Company desires to appoint the Agent as its exclusive representative for the purposes of marketing and distribution of the Product(s) in the Territory and Agent wishes to accept such appointment.  Therefore, in consideration of the following conditions set forth in this Agreement, the parties hereto agree to the following.

1.

Agency Grant

1.1.       

Grant Of License. Subject to the terms and conditions set forth herein and for the duration thereof and in consideration of Agent’s agreement to pay the Company the fees and payments hereunder, the Company hereby grants the Agent and the Agent hereby accepts a right and license to sell, market, and distribute the Product in the Territory and to make use of the trademark “Fuel Doctor” (“Marks”). 

1.2.       

Reserved Rights. All rights not specifically granted to the Agent hereunder are reserved by the Company. Except as expressly provided hereunder in connection with the sales, marketing and distribution of the Product, the Company does not convey any Intellectual Property to the Agent hereunder. Without derogating from any of the foregoing and except as provided herein, the license granted to the Agent in this Agreement shall not enable the Agent to, and the Agent shall not: (i) attempt to discover, obtain, revise, modify or enhance the components of the Product, and not attempt to decompile, disassemble, or otherwise reverse engineer the Product or enable any third party to do the same; and (ii) sell, license (or sub-license), lease, assign, transfer, pledge, or share the rights pursuant to this Agreement with/to any third party.  Except as provided herein, this Agreement shall not be construed, defined, interpreted or understood as limiting or binding the Company, in any manner whatsoever, to promote, advertise, market, distribute, sell, lease or license the Product, itself and/or via the assistance of any third party. The Agent acknowledges that the Intellectual Property in connection with the Product is the property of the Company and the Agent has no rights, express or implied, in the foregoing except those expressly granted by this Agreement and the Product shall not be used by the Agent for any other purpose, including, without limiting the generality of the foregoing, for any commercial or business purposes.

1.3.      

Exclusivity 

1.3.1. 

Subject to securing agreed minimum purchase orders as set forth in Appendix 1, the Agent will have an exclusive license to sell and market the Product in the Territory (for quantities see attached (Appendix 1). The agent must meet these minimum quantities in order to keep the exclusive distribution rights in the territory. The Company must produce and timely deliver the above quantities, in accordance with the provisions of this Agreement. In the event that the Agent shall meet the aforementioned minimum quantities, the Company agrees that any Product(s) orders or Product(s) inquiries that it may receive with respect to placements within the Territory shall be transmitted to Agent. The Company will not sell Products to anyone in the Territory, except as set forth herein.  A breach of this provision is considered material.

1.3.2. 

For the avoidance of any doubt, the minimum quantities stated in section 1.3.1 above, are referring to units actually ordered by the Agent, in accordance with the terms and provisions of this Agreement.

1.3.3.

It is hereby agreed that in the event that the Agent shall secure purchase orders of the Product in a quantity that exceeds the mentioned above minimum quantities in a specific annum, than the minimum quantity demand in the next annum shall be reduced in a measure of the extra quantity (actual quantity – minimum quantity).

1.3.4.

In any event that the Company shall not be able to supply the quantities mentioned in this Agreement, it is agreed that the parties shall negotiate the effect of such capability in amicable manner.  

1.3.5.

It is hereby agreed and declared that the Company shall have the right to terminate this Agreement with immediate effect, in any event that the Agent fails to meet with the stated minimum quantities.

1.4.       

Termination. This Agreement may be terminated by the Company in the event that the Agent has committed a material breach of any of its obligations hereunder that has not been cured within thirty (30) days after the Agent has received a written notice of such breach.

1.5.       

Modifications to the Product. The Company reserves its right and discretion to discontinue developing, producing, licensing, or distributing the Product, and/or to modify and/or to make changes in the Product, at any time with sixty (60) days prior notice to Agent. It is hereby agreed and declared that any future development or improvement of the Product by the Company or any kind of knowledge in connection with the current applications of the Product shall be solely made and owned by the Company and the Agent shall not have any rights in such developments and/or knowledge. The Company shall keep the Agent reasonably advised of any improvements and modifications of the Product.

This provision shall be effective even if such developments and/or knowledge shall be achieved by using the Agent’s funding and even if such developments and/or knowledge shall be achieved during the period of this Agreement. 

2.

Distribution & Marketing 

2.1.       

Cost of Distribution. All costs relating to selling, marketing, shipping and distribution of the Product, shall be solely borne by the Agent. 

2.2.       

Marketing Commitment. The Agent shall promote vigorously and aggressively the acquisition of the Product by end users. Notwithstanding the foregoing, any and all material, which the Agent intends to use for the purpose of promoting the Product, shall not contain information or statements, regarding the Product, differing from those contained in the Company's promotional materials and/or this Agreement, unless agreed upon by both the company and agent.

2.3.       

Projected Sales Plan. The Agent shall submit to the Company by no later than October 1st of each year, a yearly sales plan (“Sales Plan”), detailing its forecast and estimate of expected annual and quarterly sales of the units of the Product for the coming year. The Agent shall take all necessary actions in order to execute the Sales Plan and fulfill the expectations contained thereto. All costs pertaining to the foregoing execution shall be solely borne by the Agent.

2.4.       

Delivery & Acceptance. The Company shall deliver to the Agent no later than 30 days after receipt of the deposit called for in this Agreement at section 4.3, the units of the Product on a FOB. Any taxes, duties and levies will be borne solely by the Agent. If the Agent does not provide written rejection of any unit of the Product within sixty (60) days of the actual date of delivery by the Company to the Agent, the units shall be deemed accepted upon the expiry of the foregoing period. It is hereby agreed that title and risk of loss to the Products under this Agreement shall pass to Agent from the Company FOB upon delivery thereof to the carrier.

2.5.       

Minimum Quantity Per Each Order Each and every purchase order made by the Agent, according to this Agreement shall not be less than 5,000 units of the Product (“Minimum quantity per order obligation”). Notwithstanding the aforesaid, it is hereby agreed that first purchase order made by the Agent shall not be subject to the Minimum quantity per order obligation.  With the exception of 1st test order totaling 3000 units.

2.6.       

Sell Price Range to End Users It is hereby agreed that the sell price of each unit of the Product to the end users shall be retail price not less than $49.95 US Dollars and shall not exceed the amount of $89.00 US Dollars. It is hereby agreed that only for the purpose of selling units of the Product in the Fuel Doctor Europe website, (to be determined), the retail price of each unit shall not be less than the stated retail price and should be higher, $5-$10(TBD)  but shall not exceed the amount of $89.00 US Dollars for the FD-47 Product.  The FD-65 truck series price per unit shall be determined by Company.

2.7  

Sales Report The Agent shall submit to the Company each and every quarter, a sales report, detailing the number of the units of Product that has been actually sold by the Agent to distributors and retailers in the previous quarter in each Country in the Territory. All costs pertaining to the foregoing execution shall be solely borne by the Agent.

3.

Support Services Obligations

The Agent shall have the sole responsibility to make available and provide to its   customers timely, professional and adequate support services in accordance with the highest professional standards prevailing in the industry.

2

4.

Ordering and Payment

4.1.      

Purchase Orders. Purchase Orders of the Product shall be in writing and be subject to acceptance by the Company. Such orders shall set forth the quantities to be purchased and the delivery dates. The Company shall have ten (10) business days to accept or decline the purchase order. In the event the Company cannot meet the quantity or dates specified, it shall notify the Agent, and the parties shall in good faith negotiate a mutually satisfactory schedule. Each order issued hereunder shall be governed by the terms of this Agreement. It is agreed that once a purchase order is approved by the Company, the Agent may not cancel and/or modify it and is obligated to pay for such purchase order in full, unless otherwise agreed upon by the Company.

4.2.      

Payments In consideration for the license granted to the Agent pursuant to Section 2 to this Agreement and for providing the Product, the Agent shall pay the Company fee in accordance with the following scale:

4.2.1.   

[*] units in one order- $[*]USD NET per unit FOB Bangkok, Thailand or FOB LOS ANGELES (packaged in cardboard box with hanger, including [*] units in a counter top display (TBD) in [*] inner carton, and [*] inner cartons ( Total of [*]units) in [*] master.)

4.2.2.   

Initial 1 time SET-UP   fee is waived for use of all existing marketing tools (website, packaging, specials, commercials etc.) 

4.2.3. 

50% deposit to be paid upon Purchase Order submission to Company. Balance of 50% to be paid prior to first shipment. With the exception of 1st test order totaling [*] units.

It is hereby agreed and declared that the mentioned above fees/costs shall be granted to the Agent for a period of 12 months, and thereafter the Company and Agent may mutually agree on any price modification. In the event that the parties fail to agree upon such price modifications, this Agreement shall be terminated with immediate effect. 

For the avoidance of any doubt, the mentioned above fees are exclusive of any applicable taxes, duties, and levies of any kind whatsoever, however designated by any federal state or local governmental agency. In the event that the mentioned above fees are subject to withholding tax, that the fees shall increase in the proportion of the withholding tax, such that after such withholding, the Company shall receive stated above net of any withholding.

4.3.       

Payments Terms 50% of Company’s consideration for each Purchase Order placed by the Agent shall be paid by the Agent no later than the date of the Company’s acceptance of such purchase order. Balance of payment on each Purchase Order placed by the Agent will be due and payable in full, prior to delivery of the Product to the Agent and subject to bill of lading which shall be submitted to the Agent by the Company prior to each delivery. 

Company does not currently offer financing or terms to any Agent. If Agent cannot stay within payment terms of the master Distribution contract, Company can discuss 2 options: Option 1; Agent relinquishes its Agency agreement to become a commissioned sales agent in said territory for either Company or newly designated Agent, or Option 2; Company may try and reach an amicable payment arrangement after the 6 month preliminary period (subject to agreed upon terms).

4.4.       

Failure to Pay. Any payment or part of a payment that is not paid by the Agent to the Company when due shall bear interest at the rate of 1.5% per month, and shall constitute sufficient cause for the Company to immediately suspend its performance hereunder and terminate the Agreement.

4.5.       

Taxes and Expenses. Except as expressly provided in this Agreement, each party shall bear all its own taxes and expenses incurred in rendering performance.

5.

Intellectual Property Rights

5.1.       

Definition “Intellectual Property” - means all intangible legal rights, titles and interests evidenced by or embodied in (i) any invention (whether patentable or un-patentable and whether or not reduced to practice), all improvements thereto, and all patent, patent applications and patent disclosures; (ii) any work of authorship, regardless of copyrightability, copyrightable works, all copyrights (including the droit morale rights); (iii) all trade secrets and Confidential Information; and (vi) any other similar rights, in each case on a worldwide basis.

_________________

[*] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portion.

3

5.2.       

Ownership of The Product. All Intellectual Property evidenced by or embodied in and/or related to the Marks and the Product and/or any derivative work thereof or invention relating thereto, shall be owned solely by the Company. The Company has not been determined to be infringing any patents or similar rights with respect to the Products. The Agent acknowledges that except for the right of use expressly provided hereunder in connection with the marketing and selling the Product or any units of the Product, the Company does not convey any Intellectual Property to the Agent hereunder, and that the Agent has not, does not, and shall not acquire any intellectual property rights with respect to the Product, and/or any invention relating thereto.

5.3.       

The Agent’s Obligations. The Agent shall: (i) not attempt to obtain, receive, review, or otherwise use or have access to the Product (or any part thereof) by any means other than through delivery of the Product to the Agent by the Company; (ii) refrain from reverse engineering, disassembling or modifying the Product, or granting any other third party the right to do so; (iii) not engage, itself or through the assistance of any third party, directly or indirectly, in the research, development, manufacturing, marketing, distribution, sale, lease or licensing of any product which is or may constitute a derivative work of the Product (iv) not represent that it possesses any proprietary interest in the Product; and (v) not directly or indirectly, take any action to contest the Company’s Intellectual Property or infringe them in any way. 

IT IS HEREBY AGREED AND DECLARED THAT ANY BREACH OF THIS SECTION 5 AND\OR ANY ATTEMPT MADE BY THE AGENT IN ORDER TO PURCHASE THE PRODUCT FROM THIRD PARTY, SHALL GRANT THE COMPANY THE RIGHT  TO RECEIVE FROM THE AGENT AGREED COMPENSATION IN THE SUM OF $20,000,000 (TWENTY MILLION) US DOLLARS.

5.4.       

Notification. The Agent shall promptly notify the Company of Agent’s knowledge of (i) any claims, allegations, or notification that its marketing, licensing, support, or service of the Product may or will infringe the Intellectual Property of any third party; and (ii) any determination, discovery, or notification that any third party is or may be infringing the Intellectual Property of the Company. The Agent shall not take any legal action relating to the protection or defense of any Intellectual Property pertaining to the Product without the prior written approval of the Company. The Agent shall assist in the protection and defense of such Intellectual Property, however, all legal fees and costs pertaining to such protection and defense shall be borne by the Company.

6.

Confidential Information 

6.1.       

Definition “Confidential Information” means any data or information, not available to the general public, whether oral or written, treated as confidential that relates to the Product or the Company (or, if the Company is bound to protect the confidentiality of any other third party's information, such other third party's) past, present, or future research, development or business activities, including any unannounced product(s) and service(s), and including, but not limited to any information relating to services, developments, inventions, processes, plans, financial information, customer and supplier lists, forecasts, and projections.

6.2.       

Confidential Information. Insofar as Confidential Information or any portion of it is disclosed in writing and is identified as “Proprietary” and/or “Confidential” by the Company it will be received and accepted by the Agent  as Confidential Information: (i) The Agent represents and warrants that it will hold Confidential Information in confidence and protect the Confidential Information to the same extent and by the same means it uses to protect the confidentiality of its own proprietary or confidential information that it does not wish to disclose; (ii) The Agent represents and warrants that it will restrict disclosure of Confidential Information solely to those of its employees, agents, attorneys and accountants with a need to know, and will advise those individuals to whom the Confidential Information is disclosed of their obligations under this Agreement with respect to the Confidential Information, except Confidential Information will be disclosed pursuant to a Court order or pursuant to Law; provided however, that in such an event, as soon as practical after receiving the order or requirement of a court, administrative agency or other governmental body, the Agent shall give the Company a written notice of such order or requirement and in any event such notice shall be prior to disclosure of such information. (iii) all Confidential Information made available hereunder, including copies thereof, shall be returned to the Company or shall be certified as destroyed at the request of the Company.

6.3.       

Employee Agreement. The Agent shall obtain and maintain in effect written agreements with each of its employees, agents, attorneys and accountants who participate in any of the work being performed pursuant to this Agreement. Such agreements shall impose an obligation of confidence with respect to the Confidential Information enclosed by the Company.

4

7.

Non-Compete and Non-Solicitation

7.1.       

Prohibited Activities. For the term of this Agreement, for consideration to enter into this Agreement and for a period of one (1) year thereafter, the Agent shall not, without the prior written authorization of the Company, whether directly or indirectly, as an employee, independent entity, consultant, shareholder or howsoever otherwise, engage in the research and/or development of any technology, product, system, and/or device which competes with the Product, or any part thereof, and/or which imitates and/or can serve as a substitute thereof. Notwithstanding the aforesaid, for the term of this Agreement and for the period of two (2) years thereafter, the Agent shall not, without the prior written authorization of the Company, whether directly or indirectly, as an employee, independent entity, consultant, shareholder or howsoever otherwise, sell or market or distribute any technology, product, system, and/or device which competes with the Product, or any part thereof, and/or which imitates and/or can serve as a substitute thereof worldwide which competes with or can serve as a substitute to the Product, or any part thereof and/or sell or market or distribute such technology. For the purpose of this Agreement, “Compete” shall mean any product, system, device which competes with the Product, or any part thereof, and/or which imitates and/or can serve as a substitute thereof.

7.2.       

Non-Solicitation. The Agent hereby agrees that neither it nor any of its shareholders and\or affiliates, or any officers, employees or agents of it or its affiliates (each, a “Covered Person”) shall at any time during the term of this Agreement or for a period of one year thereafter, solicit the employment of, seek to employ or employ, or engage the services in any capacity of any individual who was employed by the Company at any time during the previous year or who rendered services to or for the benefit of the Agent or any affiliate thereof.  In addition and under the time periods set forth in this paragraph 7.2, no Covered Person shall induce or encourage any individual to leave the employ of the Company or to cease rendering services to or for the benefit of the Company.  

7.3.       

Restrictions - Fairness. The Agent acknowledges that the restrictions contained in Section 7.1 and 7.2 are fair and reasonably required to protect the interest of the Company pursuant to the terms and conditions contained herein, and that these restrictions will not deprive the Agent of an opportunity to earn a living or to produce a profit. The Agent acknowledges and agrees that the foregoing covenant not to compete and/or not to solicit the employees and/or consultants of the Company is part of the Company’s consideration under this Agreement and that any breach of the foregoing covenant will deprive the Company substantially of its consideration in an amount of injury that would be impossible or difficult to fully ascertain. The Company shall, therefore, be entitled to obtain an injunction restraining any violation, further violation or threatened violation of the covenant not to compete and/or not to solicit set forth above, in addition to any other remedies which the Company may pursue, as well as immediately cease any of Agent’s right of exclusivity, as stipulated in section 2.3 above.

7.4.       

Severability. The period of time, geographical area and scope of restrictions on the Agent's activities are intended to be divisible, so that if any provision of such covenant not to compete and/or not to solicit is found invalid, that provision shall be automatically modified to the extent necessary to make it valid, rather than such provision being declared invalid or void for such reason. 

8.

Warranty Disclaimer Limitation Of Liability And Product Return 

8.1.       

Customer Warranty The Company shall supply the Product in accordance with standards generally accepted in the manufacture of the units of the Products.   The Company warrants to customers that, for a period of one year from the date of shipment of any new Product, the Product will be free from defects in workmanship and material. Warranty service will be performed by the Company. This warranty is limited to repairing or replacing, at Company’s option, any Products or parts thereof that Company determines are covered by this warranty and are defective in workmanship or material.  In the event the Company determines that the Products are covered by this warranty, Company shall prepay international return shipping charges pertaining to this agent’s territory.  In all other instances, such charges shall be paid by customer.  This warranty does not extend to any Products that have been subjected (at Company’s discretion) to misuse, neglect, accident, or modification by anyone.  Agent shall inspect the Product promptly upon receipt thereof at the shipping destination and may reject any Product which fails in any significant respect to meet the quality expected of the Product based solely on Agent’s discretion.  Rejected goods shall be returned freight prepaid to Company within fourteen (14) days of rejection.  As promptly as possible, but not later than ten (10) days after receipt by Company of properly rejected goods, Company shall replace properly rejected Product.  The Company will prepay transportation charges back to the Agent and shall reimburse Agent for any costs of transportation incurred by Agent in connection with the return to Company of properly rejected Product.

8.2.      

EXPRESS DISCLAIMER. THE COMPANY MAKES NO WARRANTIES OR REPRESENTATIONS AS TO THE PRODUCT, EXCEPT AS SET FORTH HEREIN.  

5

8.3.      

LIMITATION OF LIABILITY. THE LIABILITY OF THE COMPANY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE SUPPLY OF PROCUCT HEREUNDER, SHALL BE LIMITED TO THE LOWER BETWEEN $200,000 US DOLLAR (TWO HUNDRED THOUSAND US DOLLARS) AND THE ACTUAL AMOUNTS PAID BY THE AGENT TO THE COMPANY FOR THE UNITS OF THE PRODUCT IN THE PREVIOUS 12 MONTHS, GIVING RISE TO SUCH DAMAGES, AND SHALL IN NO EVENT INCLUDE LOSS OF PROFITS, COST OF PROCURING SUBSTITUTE GOODS OR SERVICES, OR ANY INCIDENTAL, INDIRECT OR CONSEQUENTIAL DAMAGES OF ANY KIND, EVEN IF THE COMPANY IS AWARE OF THE POSSIBILITY OF SUCH DAMAGES. 

9.

Insurance.

During the term of this Agreement the Agent shall maintain an adequate insurance policy which is required by law in the Territory and which is sufficient to adequately protect against the risks associated with its ongoing business, including the risks which might possibly arise in connection with the transactions contemplated by this Agreement and provides that it cannot be terminated or cancelled without giving the Company thirty (30) days prior written notice. It is clarified and agreed that the coverage under such insurance policy shall not be less than $5,000,000 US Dollars (or whatever minimum product liability insurance is required). The Agent shall provide the Company with evidence of such insurance upon request and the policy shall name Company as an additional insured.  Prior to delivery of the Product, Agent shall provide to Company an insurance certification or declaration confirming the above insurance requirements are satisfied.

10.       

Indemnification

10.1.    

By The Company. The Company will defend (by counsel of its choice), indemnify and hold Agent harmless from and against any third party claims against Agent for any loss, damage, liability, or expense (including reasonable attorneys’ fees) sustained by it as result of a claim or allegation that the use of the Product, as licensed in this Agreement, infringes any Intellectual Property of any third party, as of the date hereof, provided that the Agent promptly notifies The Company in writing of the claim and Company has sole control of its defense and settlement; and receives reasonable assistance from the Agent in its defense and settlement. Upon notice of an alleged infringement, or upon the Company’s conclusion that such a claim is likely, the Company shall have the right, at its option, to obtain the right for the Agent to continue to exercise the rights granted under this Agreement, substitute other products with similar operating capabilities, or modify the Product so that it is no longer infringing. If none of the above options are reasonably available in the Company’s sole discretion, the Agent may terminate this Agreement and the Agent shall cease all infringing use or sale of the Product and shall return the Product and shall receive reimbursement from the Company of all amounts paid to the Company with respect thereto. Notwithstanding the foregoing, the Company shall have no liability under this Section 10.1 if the alleged infringement arises from (i) The Agent's or any End User's modification of the Product, or (ii) the combination of the Product with other equipment not provided by the Company, if such action would have been avoided but for such use or combination. The Agent shall, at its own expense, defend (by counsel selected by Company), or at the Agent’s option settle and hold the Company harmless from any action instituted against The Company resulting from any infringement claim based upon either of the foregoing. 

10.2.   

By The Agent. The Agent shall defend, indemnify and hold the Company, its Affiliates and their respective officers, directors, employees and agents harmless from and against any and all losses, demands, liabilities, costs and expenses (including reasonable attorney's fees and disbursements) incurred by or imposed upon any of them arising out of any and all governmental or private actions (or their insurers under rights of subrogation or otherwise)  that are related in any way to (i) the storage, use, transfer or sale including without limitation, the labeling, packaging, distribution, promotion and marketing of the units of the Product supplied by the Company to the Agent; (ii) any claim of failure by the Agent to comply with governmental requirements applicable to the Agent relating to the Product; or (iii) any negligent or willful act or omission by the Agent in connection with its performance of this Agreement or any breach by the Agent of any of its representations, warranties or covenants contained herein.

11.   

Term and Termination

11.1.

Term.  The term of this agreement shall commence as of the Effective Date, and shall continue for (5) years unless terminated earlier ("Term").  The Agent shall have the option to extend the term for an additional 5 years provided that the agent is not then in a default of this Agreement.  To exercise the option, Agent must deliver written notice to Company no earlier than 180 days or later than 90 days prior to the Term expiration date and the option shall be based on satisfying  the quantity order requirements set forth in Appendix 2 and complying with the terms and conditions of this Agreement.

11.2.   

Termination. This Agreement may be terminated (i) by either party in the event that the other party has committed a material breach of any of its obligations hereunder that has not been cured within thirty  (30) days after the breaching party has received a written notice thereof; (ii) by the Company, at its sole and absolute discretion (and with immediate effect as of the date the Company informs the Agent of its decision), in case of a change the ownership of the Agent or (iii) by mutual written agreement of the parties.

6

11.3.   

Termination Upon Bankruptcy. Effective immediately and without any requirement of notice, either party may, at its option, terminate this Agreement and/or suspend its performance in the event that: (i) the other party files a petition in bankruptcy, files a petition seeking any reorganization, arrangement, composition, or similar relief under any law regarding insolvency or relief for debtors, or makes an assignment for the benefit of creditors; (ii) a receiver, trustee, or similar officer is appointed for the business or property of such party; (iii) any involuntary petition or proceeding under bankruptcy or insolvency laws is instituted against such party and not stayed, enjoined, or discharged within 60 days; or (iv) the other party adopts a resolution for discontinuance of its business or for dissolution.

11.4.   

Consequences. Upon termination of this Agreement, the Agent shall cease all further promotion, marketing, and support of the Product. Without limiting the generality of the foregoing, the Agent shall cease all display, advertising, and use of all of the Company’s Marks. Upon termination of this Agreement: (i) the due date of all outstanding payments shall automatically be accelerated and all such payments shall become immediately due and payable; (ii) all orders or portions thereof remaining un-provided as of the effective date of termination maybe canceled by the Company, at its option; (iii) The Agent shall promptly return to the Company all plans, drawings and other tangible property representing the Company’s Confidential Information and/or Intellectual Property rights and/or any such tangible property representing the disclosed Confidential Information divulged by the Company to the Agent pursuant to this Agreement and all copies thereof; (iv) The Agent shall erase/delete any such Confidential Information held by it in electronic form, and shall confirm in writing to the Company that it has complied with its obligations under this paragraph; and (v) The Company shall have the right to repurchase of all the units of the Product in the Agent’s stock.

11.5.   

Survival. Notwithstanding any termination of this Agreement, Sections 1.2 (Reserved Rights), 5 (Intellectual Property Rights), 6 (Confidential Information), 7 (Non-Compete and Non-Solicitation), 8.2 (Disclaimer), 8.3 (Limited Liability), 10 (Indemnification), 11.4 (Consequences), 11.5 (Survival), 11.6 (Limitation on Liability), 12.9 (Governing Law), and 12.13.(Notices) shall survive and continue to be in effect in accordance with their term.

11.6.   

Limitation on Liability. Except as set forth herein, in the event of termination by either party in accordance with any of the provisions of this Agreement, neither party shall be liable to the other, because of such termination, for compensation, reimbursement or damages on account of the loss of prospective profits or anticipated sales or on account of expenditures, inventory, investments, leases or commitments in connection with the business or goodwill of the Company or the Agent. 

12.     

Miscellaneous

12.1.   

Relationship Of Parties. In performing their respective services hereunder, the Agent and the Company shall operate as, and have the status of, independent contractors and shall not act as or be an employee of the other. Neither party shall have any right or authority or assume or create any obligations or make any representations or warranties on behalf of the other party, whether expressed or implied, or to bind the other party in any respect whatsoever.

12.2.   

No Conflict. Each party represents and warrants, on a present and ongoing basis, to the other party that its commitments and the rights and privileges granted herein do not conflict with any other agreement or legal obligation.

12.3.   

Assignment. The rights of the Agent under this Agreement are restricted solely to the Agent and cannot be assigned, transferred, subleased, sublicensed, encumbered, or subject to any security interest without the written authorization of the Company.

12.4.  

Communication. All notices, requests, demands, and other communications under this Agreement shall be in writing and shall be deemed to have been duly given on the next business day following transmission by fax, email upon receipt (or refusal to receive) if hand delivered, or 3 business days after it is mailed by certified or registered mail postage prepaid, to the Parties at the following addresses, or at such other address as may be given in writing in the future by either Party to the other:

To the Company:   Fuel Doctor Holdings,Inc.

Name: Mark H. Soffa

Title:  President/CEO

Address:  23961 Craftsman Road #L, Calabasas, California. 91302

Phone:  818-224-5678 ext. 107

Facsimile: 818-224-3150

Email: mark@fueldoctorusa.com

7

To the Agent:  IMPEX HOLDING CO LTD

Name: Tzvika Hershko

Title:  Managing Director

Address: Piyaplace Building 6th floor, Tower B, Room 6C

29/1 Soi Langsuan, Ploenchit Road, Lumpini

Patumwan, Bangkok, 10330, Thai

Phone:  Tel: +66 2 6520156-8

Mobile: +66 818373733 or +66 838963334

Facsímile:  Fax : + 66 (0)2 -2548815

12.5.   

Amendment. This Agreement may only be amended by an instrument in writing signed by each of the parties hereto.

12.6.   

Waiver. Any waiver of any right or default hereunder shall be effective only if made in writing and in the instance given and shall not operate as or imply a waiver of any similar right or default on any subsequent occasion. No waiver by either party of any breach or series of breaches or defaults in performance by the other party, and no failure, refusal or neglect of either party to exercise any right, power or option given to it hereunder or to insist upon strict 

compliance with or performance of either party's obligations under this Agreement, shall constitute a waiver of the provisions of this Agreement with respect to any subsequent breach thereof or a waiver by either party of its right at any time thereafter to require exact and strict compliance with the provisions thereof.

12.7.   

Severability. Any clause, provision, or portion of this Agreement found or ruled invalid, void, illegal or otherwise unenforceable under any law or by any court, arbitrator, or other proceeding, shall be amended to the extent required to render it valid, legal and enforceable, or deleted if no such amendment is feasible, and such amendment or deletion shall not affect the enforceability of the other provisions hereof.

12.8.   

Remedies Cumulative. All rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available.

12.9.   

Governing Law.  This Agreement shall be governed and construed under the laws of United States, State of California. Each party hereby submits to the jurisdiction of the courts in the United States, State of California.

12.10. 

Headings. The headings and sub-headings contained in this Agreement are for convenience and reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

12.11. 

Entire Agreement. The parties agree that this Agreement is the complete and exclusive statement of the agreement between the parties, which supersedes all prior agreements, oral or written, and all other communications between the parties relating to the subject matter of this Agreement.

12.12. 

Compliance With Law. Agent and Company represent that each will comply with all applicable laws and regulations.

12.13. 

Signatures. This Agreement may be executed in two or more counterparts, each which shall be deemed an original, but all of which together shall constitute one and the same instrument.

8

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective authorized representatives.

PLEASE SEE SIGNATURE PAGES AND ADDENDUMS BELOW

SIGNED at Calabasas, California on this the 10th day of March 2012

For: Fuel Doctor Holdings,Inc  OTCBB: FDOC

/s/ Mark Soffa                          

Signatory: Mark Soffa

Title: President and CEO

Authority:  Seal or Corporate Stamp

SIGNED at Bangkok, Thailand on this the 10th day of March 2012

For: MPEX HOLDING CO LTD

/s/ Tzvika Hershko                 

Signatory: Mr. Tzvika Hershko

Title: Managing Director

Authority:  Seal or Corporate Stamp

APPENDIX 1 and 2 (Next Page)

                                         

9

APPENDIX 1

		
	Contract Year Ending:

	Minimum Number of Units Requirement

	First six months (04/01/2012-09/30/2012)

	6,000

	Second six months (10/01/2012-3/31/2013)

	10,000

	Second year (04/01/2013-3/31/2014)

	70,000

	Third year (04/01/2014-3/31/2015)

	200,000

	Fourth year (04/01/2015-3/31/2016)

	400,000

	Fifth year (04/01/2016-12/31/2017)

	500,000

APPENDIX 2

		
	Contract Year Ending:

	Minimum Number of Units Requirement

	Sixth year (04/01/2017-3/31/2018)

	620,000

	Seventh year (04/01/2018-3/31/2019)

	760,000

	Eighth year (04/01/2019-3/31/2020)

	900,000

	Ninth year (04/01/2020-3/31/2021)

	810,000

	Tenth year (04/01/2021-3/31/2022)

	690,000

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]